Clinical trial
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory…
NCT00128921 · University of Arkansas, Other · Terminated
Key facts
| NCT number | NCT00128921 |
|---|---|
| Title | Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma |
| Official title | A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | University of Arkansas, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | VELCADE™ |
| Enrollment | 18 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Aug 10, 2005 |
| Last update posted | Apr 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: